Limited first-line options challenge advanced #PDAC treatment.
This phase Ib/II study found that surufatinib + camrelizumab + nab-paclitaxel/ S-1 improved response rate and progression-free survival vs nab-paclitaxel + gemcitabine.
#STTT #OpenAccess: doi.org/10.1038/s413...
Limited first-line options challenge advanced #PDAC treatment. This phase Ib/II study found that surufatinib + camrelizumab + nab-paclitaxel/ S-1 improved response rate and progression-free survival vs nab-paclitaxel + gemcitabine. #STTT #OpenAccess: doi.org/10.1038/s413...
0 vue
Publié le 23/08/2026 12:30
Limited first-line options challenge advanced #PDAC treatment.
This phase Ib/II study found that surufatinib + camrelizumab + nab-paclitaxel/ S-1 improved response rate and progression-free survival vs nab-paclitaxel + gemcitabine.
#STTT #OpenAccess: doi.org/10.1038/s413...
0 commentaire
?